Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1961 1
1978 8
1979 6
1980 3
1982 4
1983 6
1984 7
1985 8
1986 9
1987 15
1988 7
1989 4
1990 9
1991 16
1992 24
1993 20
1994 23
1995 19
1996 14
1997 24
1998 23
1999 26
2000 35
2001 44
2002 54
2003 67
2004 64
2005 73
2006 93
2007 87
2008 100
2009 135
2010 173
2011 174
2012 169
2013 186
2014 216
2015 237
2016 233
2017 220
2018 193
2019 221
2020 230
2021 255
2022 231
2023 246
2024 243
2025 221
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,983 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.
Lafayette R, Tumlin J, Fenoglio R, Kaufeld J, Pérez Valdivia MÁ, Wu MS, Susan Huang SH, Alamartine E, Kim SG, Yee M, Kateifides A, Rice K, Garlo K, Barratt J; SANCTUARY Study Investigators. Lafayette R, et al. Among authors: kim sg. J Am Soc Nephrol. 2025 Apr 1;36(4):645-656. doi: 10.1681/ASN.0000000534. Epub 2024 Oct 25. J Am Soc Nephrol. 2025. PMID: 39455063
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study.
Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, Ko SH, Lee JH, Lee I, Lee BK, Won KC. Moon JS, et al. Among authors: kim sg. Diabetes Metab J. 2023 Nov;47(6):818-825. doi: 10.4093/dmj.2023.0171. Epub 2023 Nov 24. Diabetes Metab J. 2023. PMID: 38043782 Free PMC article. Clinical Trial.
Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial.
Lee JE, Yu SH, Kim SR, Ahn KJ, Song KH, Lee IK, Shon HS, Kim IJ, Lim S, Kim DM, Chung CH, Lee WY, Lee SH, Kim DJ, Cho SR, Jung CH, Jeon HJ, Lee SH, Park KY, Rhee SY, Kim SG, Park SO, Kim DJ, Kim BJ, Lee SA, Kim YH, Kim KS, Seo JA, Nam-Goong IS, Lee CW, Kim DK, Kim SW, Cho CG, Kim JH, Kim YJ, Yoo JM, Min KW, Lee MK. Lee JE, et al. Among authors: kim sg. Diabetes Metab J. 2024 Jul;48(4):730-739. doi: 10.4093/dmj.2023.0077. Epub 2024 May 20. Diabetes Metab J. 2024. PMID: 38763510 Free PMC article. Clinical Trial.
Sarcopenia: how to determine and manage.
Chung JY, Kim SG, Kim SH, Park CH. Chung JY, et al. Among authors: kim sg. Knee Surg Relat Res. 2025 Mar 17;37(1):12. doi: 10.1186/s43019-025-00265-6. Knee Surg Relat Res. 2025. PMID: 40098209 Free PMC article. Review.
Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial.
Kim NH, Moon JS, Lee YH, Cho HC, Kwak SH, Lim S, Moon MK, Kim DL, Kim TH, Ko E, Lee J, Kim SG. Kim NH, et al. Among authors: kim sg. Diabetes Obes Metab. 2024 Sep;26(9):3642-3652. doi: 10.1111/dom.15705. Epub 2024 Jun 10. Diabetes Obes Metab. 2024. PMID: 38853720 Clinical Trial.
3,983 results